GSA Capital Partners LLP Purchases New Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

GSA Capital Partners LLP acquired a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,787 shares of the company’s stock, valued at approximately $263,000. GSA Capital Partners LLP owned 0.07% of iTeos Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. US Bancorp DE grew its position in iTeos Therapeutics by 206.0% in the 3rd quarter. US Bancorp DE now owns 12,076 shares of the company’s stock valued at $123,000 after acquiring an additional 8,129 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of iTeos Therapeutics by 60.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after purchasing an additional 2,646 shares during the last quarter. nVerses Capital LLC grew its holdings in shares of iTeos Therapeutics by 212.5% in the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares during the last quarter. Creative Planning increased its stake in iTeos Therapeutics by 6.5% in the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after buying an additional 1,196 shares during the period. Finally, SG Americas Securities LLC bought a new stake in iTeos Therapeutics during the 3rd quarter valued at about $126,000. 97.16% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on ITOS. Wells Fargo & Company began coverage on iTeos Therapeutics in a research note on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective on the stock. JPMorgan Chase & Co. reduced their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research report on Tuesday, November 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Friday, November 15th.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.50% of the stock is owned by insiders.

iTeos Therapeutics Price Performance

Shares of ITOS opened at $8.32 on Friday. The company’s fifty day moving average price is $9.45 and its 200-day moving average price is $13.86. iTeos Therapeutics, Inc. has a 1-year low of $7.54 and a 1-year high of $18.75. The firm has a market capitalization of $303.93 million, a PE ratio of -2.64 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, research analysts anticipate that iTeos Therapeutics, Inc. will post -3.46 EPS for the current fiscal year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.